Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial

被引：0
|
作者：
Weeding, Emma [1 ]
Fava, Andrea [1 ]
Mohan, Chandra [2 ]
Goldman, Daniel
Petri, Michelle [3 ]
机构：
[1] Johns Hopkins Univ Hosp, Baltimore, MD USA
[2] Univ Houston, Houston, TX USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1737
引用
收藏
页码：3619 / 3621
页数：3
相关论文
共 50 条
  • [41] SUCCESSFUL TREATMENT OF LUPUS NEPHRITIS WITH BELIMUMAB AND VOCLOSPORIN: A RARE CASE
    Ebrahimi, Niloufar
    Ghozloujeh, Zohreh Gholizadeh
    Momand, David
    Abdipour, Amir
    Norouzi, Sayna
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S16 - S16
  • [42] Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases
    de la Rubia Navarro, Marta
    Ivorra Cortes, Jose Rafael
    Grau Garcia, Elena
    Roman Ivorra, Jose Andres
    MEDICINA CLINICA, 2022, 159 (07): : 344 - 346
  • [43] A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
    Rovin, Brad H.
    Furie, Richard
    Teng, Y. K. Onno
    Contreras, Gabriel
    Malvar, Ana
    Yu, Xueqing
    Ji, Beulah
    Green, Yulia
    Gonzalez-Rivera, Tania
    Bass, Damon
    Gilbride, Jennifer
    Tang, Chun-Hang
    Roth, David A.
    KIDNEY INTERNATIONAL, 2022, 101 (02) : 403 - 413
  • [44] CD163+M2 macrophage tissue infiltration and urinary soluble CD163 in IgA nephropathy
    Agrawal, V.
    Singh, S.
    Kamthan, S.
    Prasad, N.
    Agarwal, V.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S21 - S22
  • [45] Increased Urinary CD163 Levels in Systemic Vasculitis with Renal Involvement
    Aierken, Xiayire
    Zhu, Qing
    Wu, Ting
    Liu, Sha Sha
    Cao, Yuan Yuan
    Cai, Xin Tian
    Aihemaiti, Ayiguzaili
    Bi, Yunwei
    Yang, Shunfan
    Zhang, Weiwei
    Li, Nanfang
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [46] URINARY MONOCYTE/MACROPHAGE RELATED MARKERS MCP-1 AND SOLUBLE CD163 REFLECT THE RENAL DISEASE ACTIVITY IN LUPUS NEPHRITIS: A CROSS SECTIONAL AND LONGITUDINAL ASSESSMENT
    Gupta, R.
    Yadav, A.
    Aggarwal, A.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 35 - 35
  • [47] URINARY CD11B AND CD163 REFLECT GLOMERULAR LEUKOCYTE ACCUMULATIONS IN ANCA-ASSOCIATED GLOMERULONEPHRITIS
    Tsuboi, Naotake
    Yokoe, Yuki
    Kitagawa, Akimitsu
    Karasawa, Munetoshi
    Imaizumi, Takahiro
    Ozeki, Takaya
    Takayuki, Katsuno
    Maruyama, Shoichi
    NEPHROLOGY, 2020, 25 : 35 - 36
  • [48] Circulating macrophage activation markers, CD163 and CD206, are associated with disease severity and treatment response in patients with autoimmune hepatitis
    Gronbaek, Henning
    Kreutzfeldt, Martin
    Jessen, Niels
    Rodgaard-Hansen, Sidsel
    Kazankov, Konstantin
    Sandahl, Thomas D.
    Vilstrup, Hendrik V.
    Moller, Holger J.
    HEPATOLOGY, 2014, 60 : 364A - 364A
  • [49] Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab
    Simeoni, Monica
    Yang, Shuying
    Tompson, Debra J.
    Dimelow, Richard
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (03) : 289 - 301
  • [50] Urinary Soluble CD163 and Disease Activity in Biopsy-Proven ANCA-Associated Glomerulonephritis
    Aendekerk, Joop P. i
    Timmermans, Sjoerd A. M. E. G.
    Busch, Matthias H.
    Potjewijd, Judith
    Heeringa, Peter
    Damoiseaux, Jan G. M. C.
    Reutelingsperger, Chris P.
    van Paassen, Pieter
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (12): : 1740 - 1748
12345